(Q63471462)

English

An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Pelin Bagci

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Sameer H Patel

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

David A Kooby

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Bassel F El-Rayes

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Charles A Staley

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

N Volkan Adsay

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Shishir K Maithel

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

0 references

publication date

8 May 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

119

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

445-453

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant therapy of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular pharmacology of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular predictors of response to chemotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress in the development of prognostic and predictive markers for gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

ERCC1: impact in multimodality treatment of upper gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27619

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27619

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22569992%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q63471462&oldid=1424921314"